



Year: 2012

Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition

Rohrmann, S ; Grote, V A ; Becker, S ; Rinaldi, S ; Tjønneland, A ; Roswall, N ; Grønbæk, H ; Overvad, K ; Boutron-Ruault, M C ; Clavel-Chapelon, F ; Racine, A ; Teucher, B ; Boeing, H ; Drogan, D ; Dilis, V ; Lagiou, P ; Trichopoulou, A ; Palli, D ; Tagliabue, G ; Tumino, R ; Vineis, P ; Mattiello, A ; Rodríguez, L ; Duell, E J ; Molina-Montes, E ; Dorronsoro, M ; Huerta, J M ; Ardanaz, E ; Jeurnink, S ; Peeters, P H M ; Lindkvist, B ; Johansen, D ; Sund, M ; Ye, W ; Khaw, K T ; Wareham, N J ; Allen, N E ; Crowe, F L ; Fedirko, V ; Jenab, M ; Michaud, D S ; Norat, T ; Riboli, E ; Bueno-de-Mesquita, H B ; Kaaks, R

Abstract: BACKGROUND: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. METHODS: Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables. RESULTS: Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (OR=1.00, 95% CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95% CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; P-interaction=0.154). CONCLUSION: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.

DOI: <https://doi.org/10.1038/bjc.2012.19>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-69752>

Journal Article

Accepted Version

Originally published at:

Rohrmann, S; Grote, V A; Becker, S; Rinaldi, S; Tjønneland, A; Roswall, N; Grønbæk, H; Overvad, K; Boutron-Ruault, M C; Clavel-Chapelon, F; Racine, A; Teucher, B; Boeing, H; Drogan, D; Dilis, V; Lagiou, P; Trichopoulou, A; Palli, D; Tagliabue, G; Tumino, R; Vineis, P; Mattiello, A; Rodríguez, L; Duell, E J; Molina-Montes, E; Dorronsoro, M; Huerta, J M; Ardanaz, E; Jeurnink, S; Peeters, P H M; Lindkvist, B;

Johansen, D; Sund, M; Ye, W; Khaw, K T; Wareham, N J; Allen, N E; Crowe, F L; Fedirko, V; Jenab, M; Michaud, D S; Norat, T; Riboli, E; Bueno-de-Mesquita, H B; Kaaks, R (2012). Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. *British Journal of Cancer*, 106(5):1004-1010.
DOI: <https://doi.org/10.1038/bjc.2012.19>

Concentrations of IGF-I and IGFBP3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Sabine Rohrmann^{1,2}, Verena A Grote², Susen Becker^{2,3}, Sabina Rinaldi⁴, Anne Tjønneland⁵, Nina Roswall⁵, Henning Grønbaek⁶, Kim Overvad⁷, Marie Christine Boutron-Ruault^{8,9}, Françoise Clavel-Chapelon^{8,9}, Antoine Racine^{8,9}, Birgit Teucher², Heiner Boeing¹⁰, Dagmar Drogan¹⁰, Vardis Dilis¹¹, Pagona Lagiou^{12,13,14}, Antonia Trichopoulou^{11,12}, Domenico Palli¹⁵, Giovanna Tagliabue¹⁶, Rosario Tumino¹⁷, Paolo Vineis^{18,19}, Amalia Mattiello²⁰, Laudina Rodríguez²¹, Eric J Duell²², Esther Molina-Montes^{23,24}, Miren Dorronsoro²⁵, José-Mariá Huerta^{26,24}, Eva Ardanaz^{27,24}, Suzanne Jeurnink^{28,29}, Petra HM Peeters³⁰, Björn Lindkvist³¹, Dorthe Johansen³², Malin Sund³³, Weimin Ye^{34,35}, Kay-Tee Khaw³⁶, Nicholas J Wareham³⁷, Naomi E Allen³⁸, Francesca L Crowe³⁸, Veronika Fedirko⁴, Mazda Jenab⁴, Dominique S Michaud^{18,39}, Teresa Norat¹⁸, Elio Riboli¹⁸, H. Bas Bueno-de-Mesquita^{28,29}, Rudolf Kaaks²

¹ Division of Cancer Epidemiology and Prevention, Institute of Social and Preventive Medicine, University of Zurich, Zürich, Switzerland

²Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

³Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany

⁴International Agency for Research on Cancer (IARC-WHO), Lyon, France

⁵Diet, Cancer and Health, Danish Cancer Society, Copenhagen, Denmark

⁶Department of Medicin V, Aarhus University Hospital, Aarhus Denmark

⁷Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark

⁸Inserm, Centre for Research in Epidemiology and Population, Health, Institut Gustave Roussy, Villejuif, France

⁹Paris South University, Villejuif, France

¹⁰Department of Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany

¹¹Hellenic Health Foundation, Athens, Greece

- ¹²WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
- ¹³Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece
- ¹⁴Department of Epidemiology, Harvard School of Public Health, Boston, USA
- ¹⁵Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy
- ¹⁶Lombardy Cancer Registry and Environmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- ¹⁷Cancer Registry and Histopathology Unit, "Civile M.P.Arezzo" Hospital, Ragusa, Italy
- ¹⁸School of Public Health, Imperial College London, UK
- ¹⁹HuGeF Foundation, Torino, Italy
- ²⁰Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
- ²¹Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain
- ²²Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
- ²³Andalusian School of Public Health, Granada, Spain
- ²⁴Consortium for Biomedical Research in Epidemiology and Public Health (CIBER) de Epidemiología y Salud Pública (CIBERESP), Spain
- ²⁵Epidemiology and health Information, Public Health Division of Gipuzkoa, Basque Regional Health Department, San Sebastian, Spain
- ²⁶Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain
- ²⁷Navarre Public Health Institute, Pamplona, Spain
- ²⁸National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- ²⁹Department of Gastroenterology and Hepatology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands
- ³⁰Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands
- ³¹Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- ³²Department of Surgery, Skåne University Hospital, SUS, Malmö, Sweden
- ³³Departments of Surgical and Perioperative Sciences, Surgery and Public Health and Clinical Medicine, Nutrition Research, Umeå University, Umeå, Sweden

³⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

³⁵The Medical Biobank at Umeå University, Umeå, Sweden

³⁶Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

³⁷Medical Research Council (MRC) Epidemiology Unit, Cambridge, UK

³⁸Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

³⁹Department of Epidemiology, Division of Biology and Medicine, Brown University, Providence, Rhode Island, USA

Running title: IGF-I, IGFBP-3 and pancreatic cancer risk

Key words: IGF-I, IGFBP-3, pancreatic cancer, cohort study

Word count: Abstract: 248

Text: 2759

References: 44

Tables: 3

Corresponding Author

Sabine Rohrmann

University of Zurich

Institute of Social and Preventive Medicine

Hirschengraben 84

8001 Zürich

Switzerland

phone +41 44 634 5256

e-mail sabine.rohrmann@ifspm.uzh.ch

Abstract

Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis and may play a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).

Methods: Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables.

Results: Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top vs. bottom quartile, p-trend 0.301), IGFBP-3 (OR=1.00, 95% CI 0.66-1.51, p-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95% CI 0.75-1.97, p-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; p-interaction=0.154).

Conclusion: Based on these results, circulating levels of components of the insulin-like growth factor axis do not appear to be risk factors for pancreatic cancer. However, based on the results of a subanalysis it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.

1 **Introduction**

2 Pancreatic cancer is one of the most common causes of cancer deaths in the
3 Western world. In Europe, 48,300 deaths in men and 46,900 deaths in women due to
4 pancreas cancer were estimated for 2008 (Ferlay *et al*, 2010). So far, only few risk
5 factors for pancreatic cancer have been clearly identified. Smoking is the major
6 established lifestyle factor known to cause pancreatic cancer accounting for up to 25-
7 30% of all pancreas cancer cases (Lowenfels & Maisonneuve, 2004). Some nutrition-
8 related factors have also been found to be associated with pancreas cancer risk,
9 including excess body weight (Berrington de Gonzalez *et al*, 2003; Jiao *et al*, 2010),
10 history of type-2 diabetes mellitus (Huxley *et al*, 2005), elevated blood levels of
11 glucose (Batty *et al*, 2004; Gapstur *et al*, 2000; Grote *et al*, 2011; Jee *et al*, 2005;
12 Stattin *et al*, 2007; Stolzenberg-Solomon *et al*, 2005) and, possibly, chronic
13 hyperinsulinemia (Stolzenberg-Solomon *et al*, 2005).

14 Insulin-like growth factors (IGFs) are multifunctional peptides that regulate cell
15 proliferation, differentiation, and apoptosis (Khandwala *et al*, 2000). IGF-I is an
16 important regulator of cell growth in the postnatal period (Khandwala *et al*, 2000).
17 Binding proteins (IGFBP-1 through IGFBP-6) modulate the biological effects of IGF-I
18 as they determine the concentration of biologically active, unbound IGF (Jones &
19 Clemmons, 1995). More than 90% of circulating IGF-I is bound to IGFBP-3 and less
20 than 1% circulates in free form (Grimberg & Cohen, 2000). Binding of IGF-I to the
21 IGF-I receptor leads to stimulation of mitogenesis in a number of cell types, to cellular
22 protection from apoptosis, and to cellular transformation (Grimberg & Cohen, 2000).
23 IGFBP-3 has growth-inhibiting properties by competitively binding IGF-I, but it also
24 has independent growth inhibiting effects, e.g. via induction of apoptosis (Rajah *et al*,
25 2002; Rajah *et al*, 1997). IGFBP activities are, among others, regulated by IGFBP

1 proteases, which may cleave IGF-BPs into fragments with lower affinity to IGFs (Nunn
2 *et al*, 1997).

3 Ohmura *et al*. (Ohmura *et al*, 1990) have shown that IGF-I can stimulate
4 pancreatic cancer cell growth *in vitro*, and that this effect is mediated by the IGF-I
5 receptor (Bergmann *et al*, 1995). The analysis of pancreatic cancer tissue revealed
6 increased IGF-I mRNA and IGF-I receptor mRNA levels compared with tissue of
7 healthy individuals (Bergmann *et al*, 1995). Similarly, increased levels of IGF-I and
8 increased IGF-I receptor expression were observed in pancreatic cancer tissue
9 compared with normal pancreas tissue (Karna *et al*, 2002). It appears that IGF-I
10 stimulation and subsequent suppression of tumour suppressor chromosome 10
11 (PTEN) activity enhance invasiveness and proliferation of pancreatic cancer cells
12 (Ma *et al*, 2010).

13 Circulating levels of IGF-1 and IGF binding proteins have been found to be
14 associated with several types of cancers, including colon (Rinaldi *et al*, 2010),
15 prostate (Roddam *et al*, 2008), and breast cancer (The Endogenous Hormones and
16 Breast Cancer Collaborative Group, 2010). However, the number of studies
17 conducted with respect to pancreatic cancer is limited as is the number of cases in
18 these studies. The results of the prospective studies are rather inconsistent,
19 however, with most studies showing no association of circulating IGF-I or IGF-BP-3
20 levels with pancreatic cancer risk (Douglas *et al*, 2010; Lin *et al*, 2004; Stolzenberg-
21 Solomon *et al*, 2004; Wolpin *et al*, 2007). Because of the inconsistencies of previous
22 studies, we examined the association between IGF-I, IGF-BP-3 and pancreatic cancer
23 in the prospective EPIC cohort including more than 400 incident cases of pancreatic
24 cancer.

25

1 **Material and Methods**

2 *Study description*

3 EPIC is a prospective cohort study that includes more than 500,000 male and
4 female participants recruited in 23 centres in 10 European countries between 1992
5 and 2000. Most centres recruited subjects from the general population, but in Utrecht
6 and Florence only women from breast cancer screening programs were recruited; the
7 Spanish and Italian centres include blood donors and the French cohort consists of
8 members of a health insurance for state school employees. A high proportion of
9 participants of the Oxford cohort are vegetarians or health-conscious volunteers. The
10 cohorts of France, Utrecht, Florence, and Norway include women only.

11 Information on lifestyle and diet was collected during baseline examination.
12 Diet was assessed using country-specific validated dietary assessment instruments
13 (Kaaks *et al*, 1997; Riboli & Kaaks, 1997). Information on smoking, alcohol
14 consumption, physical activity, education, occupation, and medical and reproductive
15 history has been collected using questionnaires and personal interviews.
16 Anthropometric measurements have been conducted during baseline examination
17 (Haftenberger *et al*, 2002).

18 Following a standardized protocol, a blood sample of 30 mL was collected in
19 all participating EPIC countries. In all centres except Oxford, blood samples were
20 stored protected from light at 5-10°C until further processing and aliquoting. In the
21 Oxford centre, blood samples were collected throughout the United Kingdom and
22 transported to the laboratory in Norfolk by mail at ambient temperature. In all centres
23 except Denmark and Sweden, 0.5-1.5 ml aliquots of serum, plasma, red blood cells,
24 and buffy coat were filled into plastic straws and stored in liquid nitrogen at -196°C. In
25 the Danish centres, 1 ml aliquots were filled into tubes and stored in the vapour

1 phase of liquid nitrogen containers (-150°C). In Sweden, the samples were stored at -
2 80°C.

3 *Selection of Case and Control Subjects*

4 Pancreatic cancer incidence data were coded according to ICD-10 and
5 included all invasive exocrine pancreatic cancers that were coded as C25 (25.0-25.3,
6 25.7-25.9). Cases were those EPIC participants who developed pancreatic cancer
7 after their recruitment into the cohort and before the end of the study period.
8 Individuals were excluded when diagnosed with another malignant tumour prior to
9 the diagnosis of pancreatic cancer, except for non-melanoma skin cancer, and when
10 no blood specimens were available for analysis. 638 incident cases of pancreatic
11 cancer occurred until December 2006; 578 of them were primary exocrine pancreatic
12 tumours. Blood specimens were available for 422 of these cases. The included 422
13 pancreatic cancer cases were similar in their characteristics to the overall 578 cases
14 with pancreatic adenocarcinoma (data not shown). Of the 422 cases, 307 (76%)
15 were microscopically confirmed. The remaining 24% were diagnosed by clinical
16 symptoms, imaging results or physical examination. Forty-one percent of the tumours
17 occurred in the head of the pancreas, followed by body (7%) and tail (5%); the rest of
18 the tumours were of unknown localization. One control, alive and free of cancer at
19 time of diagnosis of the index case, was selected for each case using incidence
20 density sampling, i.e., controls may include subjects who became a case later in time
21 and each control may be sampled more than once. Cases and controls were
22 matched by study centre, sex, age at enrolment (\pm 6 months), date at entry in the
23 cohort, time between blood sampling and time of last consumption of foods and
24 drinks (<3 hours, 3-6 hours, > 6 hours).

25 *Laboratory assays*

1 Serum IGF-I and IGFBP-3 concentrations were measured in the immunoassay
2 laboratory at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
3 Both peptides were analyzed by enzyme-linked immunosorbent assays (ELISAs)
4 purchased from Beckman Coulter. Prior to total IGF-I analysis, IGF-I was separated
5 from IGF-I binding proteins by an acid-ethanol extraction step. Cases and matched
6 controls were measured in singleton within the same batch. Each analytical batch
7 further included three different serum quality control samples. Laboratory staff was
8 blinded to the case/control status of the study samples. Intra-batch and inter-batch
9 coefficients of variation for IGF-I and IGFBP-3 were 12.8 and 12.9%, and 6.5 and
10 7.2%, respectively.

11 *Statistical analysis*

12 Conditional logistic regression was used to examine the associations of IGF-I
13 and IGFBP-3 concentrations with pancreatic cancer risk. We also computed the
14 molar ratio of IGF-I to IGFBP-3 (IGF-I/IGFBP-3 ratio) as a marker of the estimated
15 level of IGF-I biologically available to bind to its receptor. Concentrations of IGF-I and
16 IGFBP-3 as well as IGF-I/IGFBP-3 ratio were categorized into sex-specific quartiles
17 based on the distribution among all controls. Crude models took into account
18 matching criteria; multivariate models were additionally adjusted for body mass index
19 (BMI; continuous), smoking history (never, former, quitting smoking less than 10
20 years ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per
21 day, missing), and history of diabetes (self-reported or high glycated haemoglobin
22 (HbA1c) concentration [$\geq 6.5\%$]). These covariates were added in the multivariable
23 adjusted models because they were associated with pancreatic cancer, correlated
24 with IGF-1 or IGFBP-3, or changed the logistic β estimate by more than 10%. Further
25 adjustment was made for circulating C-peptide concentration, which has been

1 measured previously on the same subjects (Grote *et al*, 2011). Further analyses
2 were conducted with mutual adjustments between IGF-I and IGFBP-3
3 concentrations.

4 Sub-analyses were performed, stratified by sex, smoking status at baseline
5 (smoker/non-smoker), diabetes (defined by self-report or HbA1c concentrations (\geq
6 6.5%), waist circumference (\leq/\geq median; 96 cm for men and 80 cm for women),
7 length of follow-up (\leq/\geq 2 year of follow-up time in cases), concentration of C-peptide
8 (\leq/\geq median, 5.57 ng/mL), and microscopically verification of cases. Odds ratios (OR)
9 were estimated for quartiles of IGF-1 and IGFBP-3 concentrations as well as IGF-
10 I/IGFBP-3 ratio. Additionally, we examined the interaction between IGF-I and IGFBP-
11 3 levels (both variables were dichotomized by median concentration) in a cross-
12 classification. Statistical tests for heterogeneity were based on chi-square statistics,
13 calculated as the deviations of logistic beta-coefficients observed in each of the
14 subgroups, relative to the overall beta-coefficient. All analyses were conducted with
15 SAS version 9.2.

16

17 **Results**

18 Of 422 cases in this analysis, 46% were men (Table 1). Mean age at baseline was 58
19 years; mean age at diagnosis 63 years. Female cases had a higher BMI and waist
20 circumference than female controls, but no difference was observed among men.
21 Cases were more often smokers at baseline than controls and they more often
22 reported a diagnosis of diabetes at baseline or had elevated baseline blood levels of
23 HbA1c. IGF-1 was not statistically significantly correlated with BMI (Pearson partial
24 correlation coefficient; adjusted for age, sex, and study centre; $r = -0.07$ [95% CI -
25 0.17 to 0.03]), waist circumference ($r = -0.03$ [95% CI -0.13 to 0.08]), or circulating C-

1 peptide level (0.10 [95% CI -0.005 to 0.20]), and rather weakly with height ($r = 0.11$
2 [95% CI 0.01 to 0.21]); whereas IGFBP-3 showed correlations with BMI ($r = 0.12$
3 [95% CI 0.01 to 0.22]), waist circumference ($r = 0.13$ [95% CI 0.03 to 0.23]), and C-
4 peptide levels ($r = 0.20$ [95% CI 0.10 to 0.30]), but not with height ($r = 0.01$ [95% CI -
5 0.09 to 0.12]). IGF-1 correlated highly and significantly with IGFBP-3 ($r = 0.52$ [95%
6 CI 0.44 to 0.59]) and the molar IGF-1/IGFBP-3 ratio ($r = 0.78$ [95% CI 0.74 to 0.82]),
7 whereas the ratio showed no correlation with IGFBP-3 ($r = -0.09$ [95% CI -0.19 to
8 0.01]).

9 Circulating levels of IGF-I or IGFBP-3 were not related to the risk of pancreatic
10 cancer (Table 2). Using molar IGF-I/IGFBP-3 ratio as an indicator of free IGF-I
11 concentration, we also observed no association with pancreatic cancer risk. The
12 results were only slightly affected by different types of adjustment. Additional mutual
13 adjustment of IGF-I and IGFBP-3 also did not strongly change the observed
14 associations with pancreatic cancer. There were also no associations of IGF-I,
15 IGFBP-3 or the ratio of these two with pancreatic cancer, when using only
16 microscopically confirmed cases (Table 3).

17 In sub-analyses, we examined whether the association of IGF-I, IGFBP-3, or
18 IGF-I/IGFBP-3 with pancreatic cancer was modified by sex, smoking status, length of
19 follow-up, waist circumference, diabetes status, or circulating C-peptide
20 concentration (Table 3). With few exceptions, we did not observe statistically
21 significant heterogeneity between subgroups. Waist circumference modified the
22 association of IGF-1 and IGF-1/IGFBP-3 ratio with pancreatic cancer risk, such that
23 IGF-1 concentration were positively associated with pancreatic cancer in subjects
24 with low waist circumference when comparing quartile 3 with quartile 1; no
25 association was observed when comparing top vs. bottom quartile.-There were no

1 statistically significant associations among individuals with waist circumference below
2 above the median.

3 We cross-classified IGF-I and IGFBP-3 concentration and observed an
4 increased risk of pancreatic cancer among those with IGF-I concentration above the
5 median and IGFBP-3 concentration below the median (OR=1.72, 95% CI 1.05-2.83);
6 however, the test for interaction was not statistically significant ($p=0.154$; Table 4).

7

8 **Discussion**

9 We examined the association of components of the IGF axis in association
10 with the risk of pancreatic cancer in the largest prospective study so far without
11 finding any indication for an association with circulating levels of IGF-I and IGFBP-3.
12 There was, however, an increased risk among those with high IGF-I and concurrently
13 low IGFBP-3 concentrations, although the interaction was not statistically significant.
14 Evans et al (Evans *et al*, 1997) found no elevated serum levels of IGF-I and IGFBP-3
15 in pancreatic cancer compared with controls. In contrast, Karna et al (Karna *et al*,
16 2002) showed significant increases in serum IGF-I and IGFBP-3 levels in patients
17 with pancreatic cancer compared with control subjects. Among prospective studies, a
18 case-control study nested within the ATBC trial did not observe associations of
19 serum concentrations of IGF-1, IGFBP-3 or IGF-1/IGFBP-3 ratio with the risk of
20 pancreatic cancer (Stolzenberg-Solomon *et al*, 2004); however, this result is based
21 on a cohort of male smokers only. This null association, though, is similar to the
22 results seen in four US cohorts that were analysed together (Wolpin *et al*, 2007).
23 Only a nested case-control study conducted in Japan reported that individuals in the
24 highest quartile of IGF-I concentration had an OR of 2.31 (0.70-2.64) compared with
25 participants in the lowest quartile (Lin *et al*, 2004). A recently published study nested

1 in the PLCO cohort observed an increased risk of pancreatic cancer with increasing
2 IGF-I/IGFBP-3 molar ratio, which was interpreted as an indicator of the concentration
3 of free IGF-I (Douglas *et al*, 2010). We did not observe an increase in risk with
4 increasing IGF-I/IGFBP-3 molar ratio, but did observe that those participants with
5 high IGF-I levels above the median and low IGFBP-3 concentrations had an
6 increased risk of pancreatic cancer.

7 IGFBP-3 is supposed to have growth inhibiting properties and one would, thus,
8 expect that high IGFBP-3 concentrations are inversely associated with cancer risk.
9 On the other hand, IGFBP-3 and IGF-I are highly correlated in our cohort. In the
10 Japanese nested case-control study, IGFBP-3 concentration was positively
11 associated with pancreatic cancer risk; the risk of death from pancreatic cancer was
12 increased with increasing levels of serum IGFBP-3, with the OR for the highest
13 quartile being 2.53 (95% CI=0.93-6.85) (Lin *et al*, 2004). However, the results of
14 previous studies on different types of cancer have been inconsistent with some
15 studies indeed showing inverse associations, but some also showing no or even a
16 positive association (Renehan *et al*, 2004). Cleavage of IGFBPs by proteases results
17 in IGFBP fragments with lower affinity to IGFs and additionally influences IGF-I
18 bioavailability by reducing the amount of functional IGFBPs. It has been suggested
19 that the maintenance of normal IGFBP levels is critical to normal rates of cell growth
20 and cell death (Firth & Baxter, 2002; Nunn *et al*, 1997). It has also been discussed
21 that different assays measuring concentrations of total or intact IGFBP-3 could cause
22 differences between studies (Kaaks *et al*, 2001; Renehan *et al*, 2004; Rinaldi *et al*,
23 2005). We measured intact IGFBP-3, not total IGFBP-3, which also includes IGFBP-
24 3 fragments that are less biologically active.

1 Most IGF-I in the circulation is produced by the liver (Pollak *et al*, 2004). A
2 major factor stimulating the hepatic production of IGF-I and IGFBP-3 is growth
3 hormone (GH) (Jones & Clemmons, 1995), but insulin also plays a central role in
4 regulating levels of IGF-I and IGFbps. For example, insulin increases the hepatic
5 levels of growth hormone receptors, thereby enhancing liver synthesis of IGF-I, and
6 in addition insulin increases bioactivity of IGF-I by inhibiting the synthesis of IGFBP-1
7 (Kaaks & Lukanova, 2001; Lee *et al*, 1997). Therefore, we stratified our analysis by
8 circulating C-peptide concentration to evaluate whether the association between IGF-
9 1 and IGFBP-3 and pancreatic cancer was different in individuals with high or low C-
10 peptide levels. However, we observed no statistically significant interaction, which is
11 similar to what Wolpin *et al*. had observed in their analysis (Wolpin *et al*, 2007). We
12 also examined whether other factors that are either well-known risk factors for
13 pancreatic cancer or are associated with IGF-I concentration modified the effect of
14 IGF-I or IGFBP-3 on pancreatic cancer risk. However, none of the factors examined
15 modified the observed association. We only observed statistically significant
16 interactions of waist circumference with levels of IGF-I or IGF-I/IGFBP-3 ratio, but the
17 associations in the respective subgroups were not consistently statistically significant.

18 In the EPIC cohort, only one blood sample has been collected at baseline. It
19 might be that repeated measurements of IGF-I and IGFBP-3 more accurately reflect
20 circulating levels at different points in time. However, single serum measurements of
21 IGF-I and IGFBP-3 generally have been found to be quite representative of serum
22 concentrations over longer time periods. In a study within the New York University
23 Women's Health Study cohort, Spearman's rank correlations between repeat
24 measurements in serum samples collected over time periods of more than one year
25 were 0.87 and 0.73, respectively, for IGF-I and IGFBP-3 (Lukanova *et al*, 2004).

1 Other research groups have reported similar levels of reproducibility for circulating
2 IGF-I and IGFBP-3 (Chan *et al*, 1998; Goodman-Gruen & Barrett-Connor, 1997).

3 In conclusion, our results generally do not support the hypothesis that
4 circulating levels of IGF-1 and IGFBP-3 or the molar IGF-I/IGFBP-3 ratio are
5 associated with the risk of pancreatic cancer, which confirms the results of most
6 previous prospective studies. However, it is noteworthy that individuals with high
7 circulating IGF-I and low IGFBP-3 levels have an increased risk of pancreatic cancer
8 compared to those with low IGF-I and high IGFBP-3 concentration.

9

10

11

1 **Acknowledgments**

2 We thank Miss Britta Lederer and Miss Sigrid Henke for their excellent work in
3 performing the immunoassays.

4

5 **Funding**

6 VAG is funded by the Deutsche Forschungsgemeinschaft, Graduiertenkolleg 793.

7 The coordination of EPIC is financially supported by the European Commission (DG-
8 SANCO) and the International Agency for Research on Cancer. The national cohorts
9 are supported by Danish Cancer Society (Denmark); LigueContre le Cancer,
10 InstitutGustaveRoussy, MutuelleGénérale de l'EducationNationale, Institut National
11 de la Santé et de la RechercheMédicale (INSERM) (France); Deutsche Krebshilfe,
12 Deutsches Krebsforschungszentrum (DKFZ) and Federal Ministry of Education and
13 Research (Germany); Ministry of Health and Social Solidarity, Stavros Niarchos
14 Foundation and Hellenic Health Foundation (Greece); Italian Association for
15 Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of
16 Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK
17 Research Funds, Dutch Prevention Funds, Dutch ZON (ZorgOnderzoek Nederland),
18 World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands);
19 ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on
20 Food, Nutrition and Health. (Norway); Health Research Fund (FIS), Regional
21 Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII
22 RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council
23 and Regional Government of Skåne and Västerbotten (Sweden); Cancer Research
24 UK, Medical Research Council, Stroke Association, British Heart Foundation,

- 1 Department of Health, Food Standards Agency, and Wellcome Trust (United
- 2 Kingdom).

- 1 References:
2
3 Batty GD, Shipley MJ, Marmot M, Smith GD (2004) Diabetes status and post-load plasma
4 glucose concentration in relation to site-specific cancer mortality: findings from the
5 original Whitehall study. *Cancer Causes Control* **15**: 873-81
6
7 Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth
8 factor I overexpression in human pancreatic cancer: evidence for autocrine and
9 paracrine roles. *Cancer Res* **55**: 2007-11
10
11 Berrington de Gonzalez A, Sweetland S, Spencer E (2003) A meta-analysis of obesity and
12 the risk of pancreatic cancer. *Br J Cancer* **89**: 519-23
13
14 Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak
15 M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective
16 study. *Science* **279**: 563-6
17
18 Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ
19 (2010) Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of
20 pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
21 *Cancer Epidemiol Biomarkers Prev* **19**: 2298-306
22
23 Evans JD, Eggo MC, Donovan IA, Bramhall SR, Neoptolemos JP (1997) Serum levels of
24 insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not
25 elevated in pancreatic cancer. *Int J Pancreatol* **22**: 95-100
26
27 Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and
28 mortality in Europe in 2008. *Eur J Cancer* **46**: 765-81
29
30 Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding
31 proteins. *Endocr Rev* **23**: 824-54
32
33 Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A (2000) Abnormal Glucose
34 Metabolism and Pancreatic Cancer Mortality. *JAMA* **283**: 2552-2558
35
36 Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-
37 I in elderly men and women. The Rancho Bernardo Study. *Am J Epidemiol* **145**: 970-6
38
39 Grimberg A, Cohen P (2000) Role of insulin-like growth factors and their binding
40 proteins in growth control and carcinogenesis. *J Cell Physiol* **183**: 1-9
41
42 Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, Overvad K,
43 Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H,
44 Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Panico S,
45 Rodriguez L, Duell EJ, Molina-Montes E, Dorransoro M, Huerta JM, Ardanaz E, Jeurnink
46 SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham
47 N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno-de-
48 Mesquita HB, Kaaks R (2011) Diabetes mellitus, glycated haemoglobin and C-peptide

1 levels in relation to pancreatic cancer risk: a study within the European Prospective
2 Investigation into Cancer and Nutrition (EPIC) cohort. *Diabetologia* **54**: 3037-46
3
4 Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella
5 MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, Rodriguez M,
6 Quiros JR, Berglund G, Janlert U, Khaw KT, Spencer EA, Overvad K, Tjonneland A, Clavel-
7 Chapelon F, Tehard B, Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazi G, Riboli E,
8 Slimani N (2002) Overweight, obesity and fat distribution in 50- to 64-year-old
9 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC).
10 *Public Health Nutr* **5**: 1147-62
11
12 Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M
13 (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer*
14 **92**: 2076-83
15
16 Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and
17 cancer risk in Korean men and women. *JAMA* **293**: 194-202
18
19 Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer R, Park Y, Freedman D, Gail M,
20 Alavanja M, Albanes D, Beane Freeman L, Chow W-H, Huang W-Y, Hayes R, Hoppin J, Ji B-
21 t, Leitzmann M, Linet M, Meinhold C, Schairer C, Schatzkin A, Virtamo J, Weinstein S,
22 Zheng W, Stolzenberg-Solomon R (2010) Body mass index, effect modifiers, and risk of
23 pancreatic cancer: a pooled study of seven prospective cohorts. *Cancer Causes Control*
24 **21**: 1305-1314
25
26 Jones JJ, Clemmons DR (1995) Insulin-like growth factors and their binding proteins:
27 biological actions. *Endocr Rev* **16**: 3-34
28
29 Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-
30 like growth factor-I. *Proc Nutr Soc* **60**: 91-106
31
32 Kaaks R, Rinaldi S, Lukanova A, Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P
33 (2001) Correspondence re: Giovannucci et al., A prospective study of plasma insulin-like
34 growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. *Cancer*
35 *Epidemiol. Biomark. Prev.*, 9: 345-349, 2000. *Cancer Epidemiol Biomarkers Prev* **10**:
36 1103-4
37
38 Kaaks R, Slimani N, Riboli E (1997) Pilot phase studies on the accuracy of dietary intake
39 measurements in the EPIC project: overall evaluation of results. European Prospective
40 Investigation into Cancer and Nutrition. *Int J Epidemiol* **26 Suppl 1**: S26-36
41
42 Karna E, Surazynski A, Orłowski K, Laszkiewicz J, Puchalski Z, Nawrat P, Palka J (2002)
43 Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins
44 as an index of pancreatitis and pancreatic cancer. *Int J Exp Pathol* **83**: 239-246
45
46 Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like
47 growth factors on tumorigenesis and neoplastic growth. *Endocr Rev* **21**: 215-244
48

- 1 Lee PD, Giudice LC, Conover CA, Powell DR (1997) Insulin-like growth factor binding
2 protein-1: recent findings and new directions. *Proc Soc Exp Biol Med* **216**: 319-57
3
- 4 Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, Kawamura T, Inaba Y,
5 Kurosawa M, Motohashi Y, Ohno Y (2004) Serum insulin-like growth factor-I, insulin-like
6 growth factor binding protein-3, and the risk of pancreatic cancer death. *Int J Cancer*
7 **110**: 584-8
8
- 9 Lowenfels AB, Maisonneuve P (2004) Epidemiology and Prevention of Pancreatic
10 Cancer. *Jpn J Clin Oncol* **34**: 238-244
11
- 12 Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P,
13 Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans
14 G, Toniolo P, Kaaks R (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3
15 and risk of endometrial cancer. *Int J Cancer* **108**: 262-8
16
- 17 Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato
18 M, Takeyama H (2010) IGF-1 Mediates PTEN Suppression and Enhances Cell Invasion
19 and Proliferation via Activation of the IGF-1/PI3K/Akt Signaling Pathway in Pancreatic
20 Cancer Cells. *J Surg Res* **160**: 90-101
21
- 22 Michaud DS (2004) Epidemiology of pancreatic cancer. *Minerva Chir* **59**: 99-111
23
- 24 Nunn SE, Gibson TB, Rajah R, Cohen P (1997) Regulation of prostate cell growth by the
25 insulin-like growth factor binding proteins and their proteases. *Endocrine* **7**: 115-8
26
- 27 Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, Shizume K (1990)
28 Insulin-like Growth Factor I and Transforming Growth Factor $\hat{\pm}$ as Autocrine Growth
29 Factors in Human Pancreatic Cancer Cell Growth. *Cancer Research* **50**: 103-107
30
- 31 Ojajarvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova N, Kauppinen TP,
32 Kogevinas M, Porta M, Vainio HU, Weiderpass E, Wesseling CH (2000) Occupational
33 exposures and pancreatic cancer: a meta-analysis. *Occup Environ Med* **57**: 316-24
34
- 35 Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and
36 neoplasia. *Nat Rev Cancer* **4**: 505-18
37
- 38 Rajah R, Lee KW, Cohen P (2002) Insulin-like growth factor binding protein-3 mediates
39 tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. *Cell*
40 *Growth Differ* **13**: 163-71
41
- 42 Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3
43 induces apoptosis and mediates the effects of transforming growth factor-beta1 on
44 programmed cell death through a p53- and IGF-independent mechanism. *J Biol Chem*
45 **272**: 12181-8
46
- 47 Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like
48 growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and
49 meta-regression analysis. *Lancet* **363**: 1346-53

1
2 Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European
3 Prospective Investigation into Cancer and Nutrition. *Int J Epidemiol* **26 Suppl 1**: S6-14
4
5 Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T,
6 Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno-de-
7 Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist
8 S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V,
9 Molina E, Donate Suarez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM,
10 Olsen A, Tjonneland A, Gronbaek H, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC,
11 Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R (2010) Serum levels of IGF-I,
12 IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of
13 prospective studies. *Int J Cancer* **126**: 1702-15
14
15 Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L,
16 Riboli E, Stattin P, Lukanova A, Toniolo P (2005) Insulin-like growth factor-I, IGF binding
17 protein-3, and breast cancer in young women: a comparison of risk estimates using
18 different peptide assays. *Cancer Epidemiol Biomarkers Prev* **14**: 48-52
19
20 Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss
21 NS, Fitzpatrick A, Hsing AW, Lacey JV, Jr., Helzlsouer K, Rinaldi S, Riboli E, Kaaks R,
22 Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C,
23 Quesenberry CP, Jr., Vogelmann JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G,
24 Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P
25 (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk:
26 analysis of individual patient data from 12 prospective studies. *Ann Intern Med* **149**:
27 461-71, W83-8
28
29 Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R (2007)
30 Prospective study on hyperglycemia and cancer risk. *Diabetes Care* **30**: 561-7
31
32 Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes
33 D (2005) Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers.
34 *JAMA* **294**: 2872-2878
35
36 Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D (2004)
37 Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male
38 smokers. *Cancer Epidemiol Biomarkers Prev* **13**: 438-44
39
40 The Endogenous Hormones and Breast Cancer Collaborative Group (2010) Insulin-like
41 growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled
42 individual data analysis of 17 prospective studies. *Lancet Oncology* **11**: 530-542
43
44 Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE,
45 Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS (2007) Circulating insulin-like growth
46 factor axis and the risk of pancreatic cancer in four prospective cohorts. *Br J Cancer* **97**:
47 98-104
48
49

Table 1. Baseline characteristics of pancreatic cancer cases and matched controls

Variable	Cases (n=422)	Controls (n=422)
Male subjects, n (%)	195 (46)	195 (46)
Age at recruitment (y), mean (range)	58 (30-76)	58 (30-76)
Age at diagnosis (y), mean (range)	63 (37-82)	-
Follow-up (y), mean (range)	5.4 (0-13)	
BMI (kg/m ²), mean ± SD		
Male	26.8 ± 3.6	26.7 ± 3.7
Female	26.5 ± 4.9	25.2 ± 4.2
Height (cm), mean ± SD		
Male	174.6 ± 7.4	175.1 ± 7.7
Female	162.3 ± 6.6	161.5 ± 7.2
Waist circumference (cm), mean ± SD		
Male	96.2 ± 10.1	96.6 ± 10.3
Female	84.3 ± 12.3	81.1 ± 10.6
Smoking status, n (%) ¹		
Never	155 (37)	189 (45)
Former	130 (31)	137 (32)
Current	132 (31)	91 (22)
Education, n (%) ¹		
Primary school or less	165 (40)	158 (39)
University	82 (20)	86 (21)
Physical activity, n (%) ¹		
Active	62 (16)	60 (16)
Inactive	103 (27)	119 (31)
Alcohol intake at recruitment (g/d), mean ± SD		
Male	19.7 ± 24.4	20.4 ± 26.2
Female	9.1 ± 13.1	7.4 ± 10.6
Fasting status, n (%)		
Fasting (≥ 6 hours)	117 (28)	113 (27)
In between (3 - 6 hours)	158 (37)	163 (39)
Non fasting (< 3 hours)	66 (16)	66 (15)
Unknown	81 (19)	80 (19)
Self-reported diabetes at recruitment, n (%)	30 (7)	17 (4)
Subjects HbA1c ≥ 6.5%, n (%)	50 (12)	28 (7)
C-peptide [ng/mL], mean ± SD	6.98 ± 4.6	6.66 ± 4.5
IGF-1 [ng/mL], mean ± SD	184.8 ± 71.3	182.5 ± 68.5
Male	187.1 ± 74.1	185.7 ± 68.3
Female	182.9 ± 68.9	179.7 ± 68.7
IGFBP-3 [ng/mL], mean ± SD	4668 ± 1209	4665 ± 1085
Male	4411 ± 1267	4484 ± 1042
Female	4890 ± 1114	4821 ± 1100
IGF-1 / IGFBP-3 ratio	0.19 ± 0.06	0.18 ± 0.06

SD = standard deviation, IQR = interquartile range

¹ Percentages do not add up to 100% because not all subgroups are shown

Table 2. Relative risk [OR (95% CI)] of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio in EPIC

	Quartiles ¹				<i>P</i> trend ²	OR	<i>P</i> trend ³
	1	2	3	4		continuous	
IGF-1 men [ng/ml]	33 - 138	139 - 176	177 - 226	227 - 437		per 10 ng/mL	
IGF-1 women [ng/ml]	40 - 128	129 - 168	169 - 220	221 - 433			
No. cases / controls	103 / 104	88 / 105	115 / 106	114 / 105			
Model 1 ⁴	1.0	0.88 (0.58-1.31)	1.17 (0.76-1.81)	1.21 (0.75-1.93)	0.301	1.01 (0.98-1.04)	0.499
Model 2 ⁵	1.0	0.88 (0.58-1.34)	1.21 (0.77-1.90)	1.14 (0.70-1.85)	0.475	1.01 (0.98-1.04)	0.526
Model 3 ⁶	1.0	0.88 (0.58-1.35)	1.23 (0.78-1.94)	1.15 (0.70-1.88)	0.469	1.01 (0.98-1.04)	0.460
Model 4 ⁷	1.0	0.86 (0.55-1.35)	1.21 (0.74-1.98)	1.13 (0.67-1.92)	0.542	1.01 (0.98-1.04)	0.721
Model 5 ⁸	1.0	0.89 (0.56-1.42)	1.27 (0.75-2.14)	1.21 (0.66-2.25)	0.439	1.01 (0.97-1.05)	0.597
IGFBP-3 men [ng/ml]	1625 - 3800	3825 - 4548	4550 - 5057	5092 - 9367		per 100 ng/mL	
IGFBP-3 women [ng/ml]	1698 - 4085	4087 - 4740	4745 - 5321	5342 - 11,128			
No. cases / controls	114 / 104	107 / 106	84 / 106	116 / 105			
Model 1 ⁴	1.0	0.90 (0.60-1.36)	0.72 (0.48-1.08)	1.00 (0.66-1.51)	0.789	1.00 (0.99-1.01)	0.954
Model 2 ⁵	1.0	1.00 (0.65-1.52)	0.75 (0.49-1.14)	1.13 (0.73-1.74)	0.812	1.00 (0.99-1.02)	0.593
Model 3 ⁶	1.0	1.04 (0.67-1.59)	0.76 (0.49-1.17)	1.06 (0.68-1.65)	0.941	1.00 (0.99-1.01)	0.970
Model 4 ⁷	1.0	1.05 (0.67-1.65)	0.81 (0.52-1.27)	1.07 (0.67-1.71)	0.969	1.00 (0.99-1.02)	0.696
Model 5 ⁹	1.0	1.00 (0.63-1.59)	0.76 (0.47-1.23)	0.94 (0.55-1.61)	0.673	1.00 (0.98-1.02)	0.875
IGF-I/IGFBP-3 men	0.05 - 0.15	0.16 - 0.18	0.19 - 0.22	0.22- 0.43		per 0.01	
IGF-I/IGFBP-3 women	0.05 - 0.12	0.13 - 0.16	0.17 - 0.21	0.22 - 0.44			
No. cases / controls	103 / 104	88 / 105	112 / 105	116 / 105			
Model 1 ⁴	1.0	0.87 (0.57-1.33)	1.12 (0.73-1.72)	1.22 (0.75-1.97)	0.273	1.02 (0.99-1.05)	0.190
Model 2 ⁵	1.0	0.86 (0.55-1.33)	1.10 (0.70-1.70)	1.12 (0.68-1.85)	0.480	1.01 (0.98-1.04)	0.425
Model 3 ⁶	1.0	0.96 (0.61-1.52)	1.21 (0.77-1.90)	1.29 (0.77-2.16)	0.245	1.02 (0.99-1.05)	0.207
Model 4 ⁷	1.0	0.94 (0.59-1.51)	1.14 (0.71-1.84)	1.17 (0.69-2.00)	0.467	1.01 (0.98-1.04)	0.594

CI=confidence interval, No=number

¹ quartile cut points were based on the distribution of controls² *P* trend test was based on median values of each quartile

- ³ *P* trend test was based on continuous values
- ⁴ Model 1: logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last consumption of foods and drinks).
- ⁵ Model 2: as model 1 with further adjustment for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per day, missing),
- ⁶ Model 3: as above with further adjustment for BMI (continuous) and diabetes (defined by self-report or HbA1c concentration $\geq 6.5\%$),
- ⁷ Model 4: as above with further adjustment for C-peptide concentration (continuous)
- ⁸ Model 5: as above with further adjustment for IGFBP-3 concentration (continuous)
- ⁹ Model 5: as model 3 with further adjustment for IGF-I concentration (continuous)

Table 3. Relative risk [OR (95% CI)] of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio for subgroups in EPIC

	No	Quartiles ¹				p-trend ²	p-interaction
	Ca / Co	1	2	3	4		
IGF-1 men [ng/ml]	195 / 195	33 - 138	139 - 176	177 - 226	227 - 437		
IGF-1 women [ng/ml]	225 / 227	40 - 128	129 - 168	169 - 220	221 - 433		
Non-smoker	154 / 189	1.0	1.09 (0.57-2.07)	1.63 (0.85-3.13)	1.72 (0.91-3.28)	0.068	0.445
Smokers	261 / 228	1.0	0.73 (0.42-1.26)	0.98 (0.57-1.68)	0.94 (0.54-1.64)	0.878	
Non-diabetics	349 / 374	1.0	0.88 (0.56-1.37)	1.23 (0.80-1.91)	1.20 (0.77-1.88)	0.244	0.545
Diabetics	54 / 32	1.0	1.54 (0.40-5.99)	0.69 (0.14-3.32)	0.81 (0.18-3.75)	0.629	
Years 1&2 of fup	71 / 71	1.0	0.59 (0.17-2.04)	1.09 (0.29-4.09)	1.43 (0.36-5.69)	0.417	0.946
3+ years of fup	349 / 351	1.0	0.93 (0.58-1.48)	1.26 (0.77-2.08)	1.22 (0.71-2.11)	0.391	
Male	195 / 195	1.0	0.71 (0.37-1.35)	1.18 (0.59-2.37)	1.09 (0.53-2.23)	0.553	0.746
Female	225 / 227	1.0	1.09 (0.60-1.98)	1.28 (0.68-2.42)	1.08 (0.52-2.25)	0.827	
Low C-peptide	214 / 221	1.0	0.64 (0.37-1.12)	0.85 (0.48-1.51)	1.08 (0.59-1.95)	0.513	0.398
High C-peptide	206 / 201	1.0	1.15 (0.61-2.14)	1.57 (0.87-2.84)	1.27 (0.71-2.29)	0.396	
Low waist circumference	205 / 221	1.0	0.83 (0.46-1.52)	1.80 (1.01-3.23)	1.23 (0.68-2.23)	0.246	0.040
High waist circumference	215 / 201	1.0	0.79 (0.44-1.41)	0.70 (0.38-1.27)	1.03 (0.56-1.86)	0.812	
Microscopically confirmed	305 / 307	1.0	0.95 (0.57-1.58)	1.45 (0.83-2.52)	1.10 (0.61-2.00)	0.632	

Table 3 cont.

	No	Quartiles ¹				p-trend ²	p-interaction
	Ca / Co	1	2	3	4		
IGFBP-3 men [ng/ml]	195 / 195	1625 - 3800	3825 - 4548	4550 - 5057	5092 - 9367		
IGFBP-3 women [ng/ml]	227 / 226	1698 - 4085	4087 - 4740	4745 - 5321	5342 - 11128		
Non-smoker	155 / 189	1.0	1.00 (0.53-1.89)	0.77 (0.40-1.47)	0.94 (0.50-1.79)	0.701	0.974
Smokers	262 / 227	1.0	0.94 (0.55-1.59)	0.73 (0.42-1.26)	1.05 (0.62-1.77)	0.987	
Non-diabetics	351 / 373	1.0	1.02 (0.67-1.55)	0.69 (0.44-1.08)	0.99 (0.64-1.52)	0.622	0.694
Diabetics	54 / 32	1.0	0.61 (0.13-2.82)	1.13 (0.25-5.16)	1.12 (0.27-4.61)	0.797	
Years 1&2 of fup	71 / 70	1.0	1.68 (0.59-4.78)	1.36 (0.44-4.23)	1.44 (0.46-4.47)	0.612	0.724
3+ years of fup	351 / 351	1.0	0.94 (0.58-1.52)	0.69 (0.43-1.13)	1.12 (0.68-1.85)	0.855	
Male	195 / 195	1.0	0.78 (0.41-1.46)	0.54 (0.28-1.04)	0.96 (0.50-1.84)	0.774	0.362
Female	227 / 226	1.0	1.37 (0.74-2.56)	1.03 (0.56-1.90)	1.17 (0.61-2.25)	0.915	
Low c-peptide	215 / 221	1.0	0.78 (0.45-1.35)	0.66 (0.37-1.16)	0.64 (0.36-1.14)	0.088	0.198
High c-peptide	207 / 200	1.0	1.21 (0.66-2.23)	0.78 (0.42-1.45)	1.47 (0.82-2.65)	0.277	
Low waist circumference	206 / 221	1.0	0.74 (0.43-1.30)	0.57 (0.32-1.02)	0.92 (0.51-1.63)	0.632	0.654
High waist circumference	216 / 200	1.0	1.26 (0.69-2.27)	0.91 (0.49-1.68)	1.05 (0.59-1.87)	0.825	
Microscopically confirmed	307 / 306	1.0	0.98 (0.57-1.66)	0.65 (0.38-1.12)	0.94 (0.55-1.62)	0.624	

Table 3 cont.

	No Ca / Co	Quartiles ¹				p-trend ²	p-interaction
		1	2	3	4		
IGF-I/IGFBP-3 men	195 / 195	0.05 - 0.15	0.16 - 0.18	0.19 - 0.22	0.22- 0.43		
IGF-I/IGFBP-3 women	225 / 226	0.05 - 0.12	0.13 - 0.16	0.17 - 0.21	0.22 - 0.44		
Non-smoker	154 / 189	1.0	1.08 (0.56-2.11)	1.54 (0.81-2.92)	1.83 (0.94-3.57)	0.052	0.683
Smokers	261 / 227	1.0	0.81 (0.47-1.39)	1.03 (0.60-1.75)	1.16 (0.67-1.99)	0.442	
Non-diabetics	349 / 373	1.0	1.02 (0.65-1.59)	1.27 (0.82-1.97)	1.39 (0.89-2.17)	0.097	0.543
Diabetics	54 / 32	1.0	0.28 (0.06-1.29)	1.00 (0.25-4.08)	0.91 (0.18-4.59)	0.923	
Years 1&2 of follow-up	71 / 70	1.0	1.23 (0.26-5.75)	2.05 (0.38-11.08)	0.85 (0.18-4.03)	0.761	0.513
3+ years of follow-up	349 / 351	1.0	1.01 (0.62-1.63)	1.20 (0.75-1.94)	1.45 (0.83-2.54)	0.163	
Male	195 / 195	1.0	0.49 (0.24-0.98)	1.07 (0.55-2.08)	1.28 (0.62-2.64)	0.161	0.050
Female	225 / 226	1.0	1.45 (0.76-2.77)	1.31 (0.67-2.55)	1.18 (0.52-2.65)	0.856	
Low C-peptide	214 / 221	1.0	0.64 (0.36-1.16)	0.91 (0.50-1.64)	1.20 (0.67-2.17)	0.254	0.423
High C-peptide	206 / 200	1.0	1.42 (0.78-2.60)	1.33 (0.77-2.32)	1.35 (0.75-2.45)	0.370	
Low waist circumference	205 / 221	1.0	0.85 (0.46-1.56)	1.73 (0.94-3.17)	1.33 (0.73-2.39)	0.162	0.028
High waist circumference	215 / 200	1.0	1.01 (0.56-1.81)	0.75 (0.43-1.30)	1.35 (0.74-2.48)	0.491	
Microscopically confirmed	305 / 306	1.0	1.25 (0.72-2.18)	1.52 (0.88-2.61)	1.49 (0.81-2.72)	0.195	

¹ Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last consumption of foods and drinks) and adjusted for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per day, missing), BMI (continuous) and diabetes (defined by self-report or HbA1c concentrations $\geq 6.5\%$)

² P trend test was based on median values of each quartile

Table 4. Joint effect of IGF-1 and IGFBP-3 concentrations on risk of pancreatic cancer [OR (95% CI)]

	< median IGF-1	≥ median IGF-1
≥ median IGFBP-3	1.0	1.48 (0.97-2.22)
< median IGFBP-3	1.47 (0.97-2.22)	1.72 (1.05-2.83)

¹ Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last consumption of foods and drinks) and adjusted for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per day, missing), BMI (continuous) and diabetes (defined by self-report or HbA1c concentrations ≥ 6.5%)

² P-interaction = 0.154